Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma - Concepedia

Concepedia

Publication | Closed Access

Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma

116

Citations

51

References

2004

Year

Maurizio Zangari, Elias Anaissie, Alison Stopeck, Alyssa Morimoto, Nguyêñ Duy Tân, Jeffrey E. Lancet, Maureen Cooper, Alison L. Hannah, Guillermo Garcia‐Manero, S. Faderl,

Clinical Cancer Research

Abstract

Although SU5416 had minimal clinical activity, signs of biological activity (decrease in plasma VEGF levels) suggest that angiogenic modulation may be of value in patients with MM.

References

	Year	Citations

Page 1